cervical cancer
Conditions
Interventions
A total dose of 50 Gy was delivered in 25 daily fractions of2.0 Gy, administered on 5 days a week CDDP: 8 mg/m2/day weekday x 25
Sponsors
Chiba University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1) Patients with stage IIA to IIIB cervical cancer according to the International Federation of Gynecologyand Obstetrics, 2) Cervical carcinoma of the non- small cell type (squamous, adenosquamous, and adenocarcinoma), were selected. 3) no previous chemotherapy or radiotherapy 4) ECOG performance status 0-2 5) Leukocyte count of 3,000/mm3 or higher, neutrophil count of 2,000/mm3 or higher, platelet count of 100,000/mm3 or higher, serum creatinine 1.5 mg/dl or less 6)) normal chest radiograph and electrocardiogram.
Exclusion criteria
Exclusion criteria: 1) positive para aortic lymph node swelling 2) severe systemic or uncontrolled disease (uncontrolled diabetes mellitus or hypertension) 3) severe infection that precluded the use of chemotherapy 4) preexisting neuropathy from any cause, pregnancy or lactation 5) mental illness 6) previous or concomitant malignancies
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival by histology Overall survival by age Adverse effects | — |
Countries
Japan
Contacts
Public ContactAKIra Mitsuhashi
Graduate School of Medicine, Chiba University Reproductive Medicine
Outcome results
None listed